Merger & Acquisition in Healthcare, Q1 2011

  • May 2012
  • -
  • Global Data
  • -
  • 86 pages



GlobalData's “Partnerships, Licensing, Investments and M&A Deals and Trends in Pharmaceuticals - Q1 2011” report is an essential source of data and trend analysis on partnerships, licensing, mergers and acquisitions (M&A) and financing in the pharmaceutical and healthcare market. The report provides detailed information on partnerships, licensing agreements, M&As, equity/debt offerings, private equity and venture financing transactions recorded in the pharmaceutical and healthcare industry in Q1 2011. The report presents detailed comparative data on the number of deals and their value in the last five quarters, categorized into deal types, segments, and geographies. The report also provides information on the top venture capital and advisory firms in the pharmaceutical and healthcare industry

This report is systematically updated by our analysts for each new purchase. This is to ensure that you get the latest information available on the company. The report will be updated and sent to you in no later than 2 business days.

SWOT Analysis report provides you a strategic analysis and detailed overview of the company’s businesses and operations.

In this report, our analysts reveal the company’s business strategy, strengths, weakness, opportunities and threats and detailed information such as :
- Key events associated with the company,
- Major products, services and brands of the company,
- Key competitors,
- Key executives, biographies and employment history,
- Personnel heading key departments and functions,
- Important locations and subsidiaries
- Financial analysis and ratios based on the annual financial statements published by the company including a 5 years history.
- Interim ratios for the last five interim periods

You get also in deepth information about operations to identify potential customers, partners and suppliers. business structure, operations, major products and services, prospects, locations and subsidiaries, key executives and their biographies and key competitors.



Latest Company Developments:

Table Of Contents

1 Table of contents

I Table of contents 2
I. 1 List of Data tables 5
I. 2 List of Charts 7

II Pharmaceutical and Healthcare, Global, Deal Summary, Q1 2011 9
II. 1 Pharmaceutical and Healthcare, World Deals Analysis, Q1 2011 9
II. 2 Pharmaceutical and Healthcare, Global, by Type, Number of Deals and Deal Values, Q1 2011 11
II. 3 Pharmaceutical and Healthcare, Global, Top Deals, Q1 2011 12
II. 3.1 Sanofi Completes Public Offering Of Notes For US$ 7 Bln 12
II. 3.2 DuPont Receives Approval From European Commission To Take Over Danisco 12
II. 3.3 Terumo To Take Over CaridianBCT From Gambro 12
II. 3.4 Eli Lilly Enters Into Co-Development Agreement With Boehringer Ingelheim 13
II. 3.5 Thermo Fisher Scientific Completes Public Offering Of Senior Notes For US$ 2.2 Bln 13

III Pharmaceuticals and Healthcare, Global, Merger and Acquisition Deal Summary, by Type 14
III. 1 Pharmaceutical and Healthcare, Global, Merger and Acquisition, Q1 2011 14
III. 1.1 Top Merger and Acquisition Deals in Q1 2011 15
III. 1.2 Pharmaceuticals and Healthcare, Global, Merger and Acquisition Deals, by Therapy Area, Q1 2010 - Q1 2011 16
III. 2 Pharmaceutical and Healthcare, Global, Equity Offering Deals, Q1 2011 17
III. 2.1 Top Initial Public Offerings in Q1 2011 18
III. 2.2 Top Secondary Offerings in Q1 2011 18
III. 2.3 Top PIPE Deals in Q1 2011 18
III. 2.4 Pharmaceutical and Healthcare, Global, Top IPOs Share Performance, Q1 2010-Q1 2011 19
III. 2.5 Pharmaceutical and Healthcare, Global, Equity Offering Deals, by Therapy Area, Q1 2010 - Q1 2011 20
III. 3 Pharmaceutical and Healthcare, Global, Debt Offering Deals, Q1 2011 21
III. 3.1 Top Public Debt Offerings in Q1 2011 22
III. 3.2 Top Private Debt Placements in Q1 2011 22
III. 3.3 Pharmaceutical and Healthcare, Global, Debt Offering Deals, by Therapy Area, Q1 2010 - Q1 2011 23
III. 4 Pharmaceutical and Healthcare, Global, Venture Capital Deals, Q1 2011 24
III. 4.1 Top Venture Financing Deals in Q1 2011 25
III. 4.2 Pharmaceutical and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Q1 2011 26
III. 4.3 Pharmaceutical and Healthcare, Global, Venture Capital, by Therapy Area, Q1 2010 - Q1 2011 27
III. 4.4 Pharmaceutical and Healthcare, Global, Top Venture Financing Firms, Last Five Quarters 28
III. 4.5 Pharmaceutical and Healthcare, Global, Top VC Backed Firms, Last One Year 29
III. 5 Pharmaceutical and Healthcare, Global, Private Equity Deals, Q1 2011 30
III. 5.1 Top Private Equity Deals in Q1 2011 31
III. 5.2 Pharmaceutical and Healthcare, Global, Private Equity Deals, by Therapy Area, Q1 2010 - Q1 2011 32

IV Pharmaceutical and Healthcare, Global, Partnership Deals, Q1 2011 33
IV. 1 Pharmaceutical and Healthcare, Global, Partnership Deals, Q1 2011 33
IV. 2 Pharmaceutical and Healthcare, Global, Partnership Deals, by Therapy Area, Q1 2010 - Q1 2011 34
IV. 3 Pharmaceutical and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payment and Deal Value (US$ m), Q1 2011 35
IV. 3.1 Pharmaceutical and Healthcare, Global, Top Partnership Deals, by Deal Values, Q1 2011 36
IV. 3.2 Pharmaceutical and Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2011 36
IV. 3.3 Pharmaceutical and Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2011 37
IV. 4 Pharmaceutical and Healthcare, Global, Partnership Deals, by Therapy Area, by Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 38
IV. 5 Pharmaceutical and Healthcare, Global, Partnership Deals, by Phase, Number Of Deals and Deal Value (US$ m), Q1 2010 - Q1 2011 39
IV. 6 Pharmaceutical and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 40

V Pharmaceutical and Healthcare, Global, Licensing Agreements, Q1 2011 41
V. 1 Pharmaceutical and Healthcare, Global, Licensing Agreements, Q1 2011 41
V. 2 Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, Upfront and Milestone Payment and Deal Value (US$ m), Q1 2010 - Q1 2011 42
V. 2.1 Pharmaceutical and Healthcare, Global, Top Licensing Agreements, by Deal Value, Q1 2011 43
V. 2.2 Pharmaceutical and Healthcare, Global, Top Licensing Agreements, by Total Upfront Payment, Q1 2011 43
V. 2.3 Pharmaceutical and Healthcare, Global, Top Licensing Agreements, by Total Milestone Payment, Q1 2011 44
V. 2.4 Pharmaceutical and Healthcare, Global, Licensing Agreements with Equity Investment, Q1 2010 - Q1 2011 44
V. 3 Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Total Deal Value (US$ m), Q1 2010 - Q1 2011 45
V. 4 Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront Payment Vs Milestone Payment (US$ m), Q1 2010 - Q1 2011 46
V. 5 Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, by Phase, Total Deal Value (US$ m), Q1 2010 - Q1 2011 47
V. 6 Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, by Phase, Upfront Payment Vs Milestone Payment (US$ m), Q1 2010 - Q1 2011 48

VI Pharmaceutical and Healthcare, Global, Merger and Acquisition Financial Analysis 49
VI. 1 Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value versus Median Deal Value, Q1 2010 - Q1 2011 49
VI. 2 Pharmaceutical and Healthcare, World Acquisitions, Average Price Earnings of Acquired Firms, Q1 2010 - Q1 2011 50
VI. 3 Pharmaceutical and Healthcare, World Acquisitions, Average EV/EBITDA of Acquired Firms, Q1 2010 - Q1 2011 51
VI. 4 Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value per Operating Profit, Q1 2010 - Q1 2011 52
VI. 5 Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value Per Share versus Average March ket Price Per Share, Q1 2010 - Q1 2011 53
VI. 5.1 Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value Per Share versus Average Book Value Per Share, Q1 2010 - Q1 2011 54
VI. 6 Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value Per Sales, Q1 2010 - Q1 2011 55

VII Pharmaceutical and Healthcare, Global, Deal Summary by Therapy Area 56
VII. 1 Pharmaceuticals and Healthcare, Global, Oncology Deals, Q1 2011 56
VII. 1.1 Oncology - Deals of the Quarter 57
VII. 2 Pharmaceuticals and Healthcare, Global, Central Nervous System Deals, Q1 2011 58
VII. 2.1 Central Nervous System - Deals of the Quarter 59
VII. 3 Pharmaceuticals and Healthcare, Global, Infectious Disease Deals, Q1 2011 60
VII. 3.1 Infectious Disease - Deals of the Quarter 61
VII. 4 Pharmaceuticals and Healthcare, Global, Immunology Deals, Q1 2011 62
VII. 4.1 Immunology - Deals of the Quarter 63
VII. 5 Pharmaceuticals and Healthcare, Global, Cardiovascular Deals, Q1 2011 64
VII. 5.1 Cardiovascular - Deals of the Quarter 65
VII. 6 Pharmaceuticals and Healthcare, Global, Metabolic Disorders, Deals, Q1 2011 66
VII. 6.1 Metabolic Disorders - Deals of the Quarter 67
VII. 7 Pharmaceuticals and Healthcare, Global, Dermatology Deals, Q1 2011 68
VII. 7.1 Dermatology - Deals of the Quarter 69
VII. 8 Pharmaceuticals and Healthcare, Global, Gastrointestinal Deals, Q1 2011 70
VII. 8.1 Gastrointestinal - Deals of the Quarter 71
VII. 9 Pharmaceuticals and Healthcare, Global, Respiratory Deals, Q1 2011 72
VII. 9.1 Respiratory - Deals of the Quarter 73
VII. 10 Pharmaceuticals and Healthcare, Global, Hematological Disorder Deals, Q1 2011 74
VII. 10.1 Hematological Disorders - Deals of the Quarter 75

VIII Deal Summary by Geography 76
VIII. 1 Pharmaceuticals and Healthcare, North America Region, Deals, Q1 2011 76
VIII. 1.1 North America - Deals of the Quarter 77
VIII. 2 Pharmaceuticals and Healthcare, Europe Region, Deals, Q1 2011 78
VIII. 2.1 Europe - Deals of the Quarter 79
VIII. 3 Pharmaceuticals and Healthcare, Asia-Pacific, Deals, Q1 2011 80
VIII. 3.1 Asia-Pacific - Deals of the Quarter 81
VIII. 4 Pharmaceuticals and Healthcare, Rest of the World, Deals, Q1 2011 82
VIII. 4.1 Rest of the World - Deals of the Quarter 83

IX Pharmaceuticals and Healthcare, Global, Top Advisors 84
IX. 1 Pharmaceutical and Healthcare, World Top Financial Advisors, Merger and Acquisition, Last One Year 84
IX. 2 Pharmaceuticals and Healthcare, Global, Top Financial Advisors, Equity Offerings, Past One Year 85

X Appendix 86

XI Further Information 88
XI. 1 Methodology 88
XI. 2 About GlobalData 89
XI. 3 Contact Us 89
XI. 4 Disclosure information 89
XI. 5 Disclaimer 89

List of Tables

Data table 1: Pharmaceutical and Healthcare, Global, Deal Summary, Number of Deals and Deal Values (US$m), Q1 2010 - Q1 2011 10
Data table 2: Pharmaceutical and Healthcare, Global, Number Of Deals and Deal Values (%), Q1 2011 11
Data table 3: Pharmaceutical and Healthcare, Global, Top Deals, Q1 2011 12
Data table 4: Pharmaceutical and Healthcare, Global, Merger and Acquisition, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 14
Data table 5: Pharmaceutical and Healthcare, Global, Top Merger and Acquisition Deals, Q1 2011 15
Data table 6: Pharmaceutical and Healthcare, Global, Merger and Acquisition, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), by Therapy Area,, Q1 2010 - Q1 2011 16
Data table 7: Pharmaceutical and Healthcare, Global, Equity Offerings, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$m), Q1 2010 - Q1 2011 17
Data table 8: Pharmaceutical and Healthcare, Global, Top Initial Public Offering Deals, Q1 2011 18
Data table 9: Pharmaceutical and Healthcare, Global, Top Secondary Offering Deals, Q1 2011 18
Data table 10: Pharmaceutical and Healthcare, Global, Top PIPE Deals, Q1 2011 18
Data table 11: Pharmaceutical and Healthcare, Global, Top IPOs Share Performance, Q1 2010-Q1 2011 19
Data table 12: Pharmaceutical and Healthcare, Global, Equity Offering Deals, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$m), Q1 2010 - Q1 2011 20
Data table 13: Pharmaceutical and Healthcare, Global, Debt Offering, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 21
Data table 14: Pharmaceutical and Healthcare, Global, Top Public Debt Offerings, Q1 2011 22
Data table 15: Pharmaceutical and Healthcare, Global, Top Private Debt Placements, Q1 2011 22
Data table 16: Pharmaceutical and Healthcare, Global, Debt Offering Deals, Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 23
Data table 17: Pharmaceutical and healthcare, Global, Venture Capital, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 24
Data table 18: Pharmaceutical and Healthcare, Global, Top Venture Capital Deals, Q1 2011 25
Data table 19: Pharmaceutical and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals and Deal Values (%), Q1 2011 26
Data table 20: Pharmaceutical and Healthcare, Global, Venture Capital Deals, by Therapy Area, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$m), Q1 2010 - Q1 2011 27
Data table 21: Pharmaceutical and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 28
Data table 22: Pharmaceuticals and Healthcare, Global, Top VC Backed Firms, Q1 2010 - Q1 2011 29
Data table 23: Pharmaceutical and Healthcare, Global, Private Equity, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 30
Data table 24: Pharmaceutical and Healthcare, Global, Top Private Equity Deals, Q1 2011 31
Data table 25: Pharmaceutical and Healthcare, Global, Private Equity Deals, by Therapy Area, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$m), Q1 2010 - Q1 2011 32
Data table 26: Pharmaceutical and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 33
Data table 27: Pharmaceutical and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 34
Data table 28: Pharmaceutical and Healthcare, Partnership Deals, Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 35
Data table 29: Pharmaceutical and Healthcare, Global, Partnerships, Upfront and Milestone Payment and Deal Values (US$ m), Q1 2011 36
Data table 30: Pharmaceutical and Healthcare, Global, Top Partnership Deals, by Upfront Payment, Q1 2011 36
Data table 31: Pharmaceutical and Healthcare, Global, Top Partnership Deals, by Milestone Payment, Q1 2011 37
Data table 32: Pharmaceutical and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 38
Data table 33: Pharmaceutical and Healthcare, Global, Partnership Deals, by Phase, Q1 2010 - Q1 2011 39
Data table 34: Pharmaceutical and Healthcare, Global, Partnership Deals, by Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 40
Data table 35: Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 41
Data table 36: Pharmaceutical and Healthcare, Global, Licensing Agreements, Merger and Acquisition Deal Summary, Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 42
Data table 37: Pharmaceutical and Healthcare, Global, Top Licensing Agreement Deals, by Deal Values, Q1 2011 43
Data table 38: Pharmaceutical and Healthcare, Global, Top Licensing Agreement Deals, by Total Upfront Payment, Q1 2011 43
Data table 39: Pharmaceutical and Healthcare, Global, Top Licensing Agreement Deals, by Total Milestone Payment, Q1 2011 44
Data table 40: Pharmaceutical and Healthcare, Global, Licensing Agreements with Equity Investment, Q1 2010 - Q1 2011 44
Data table 41: Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 45
Data table 42: Pharmaceutical and Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront and Milestone Payment (US$ m), Q1 2010 - Q1 2011 46
Data table 43: Pharmaceutical and Healthcare, Global, Partnership Deals, by Phase, Q1 2010 - Q1 2011 47
Data table 44: Pharmaceutical and Healthcare, Global, Licensing Agreements, by Therapy Area, by Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 48
Data table 45: Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2010 - Q1 2011 49
Data table 46: Pharmaceutical and Healthcare, World Acquisitions, Average P/E of Acquired Firms, Q1 2010 - Q1 2011 50
Data table 47: Pharmaceutical and Healthcare, World Acquisitions, Average EV/EBITDA of Acquired Firms, Q1 2010 - Q1 2011 51
Data table 48: Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value Per Operating Profit, Q1 2010 - Q1 2011 52
Data table 49: Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value Per Share vs Average March ket Price Per Share, Q1 2010 - Q1 2011 53
Data table 50: Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q1 2010 - Q1 2011 54
Data table 51: Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value Per Sales, Q1 2010 - Q1 2011 55
Data table 52: Pharmaceutical and Healthcare, Global, Oncology, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 57
Data table 53: Pharmaceutical and Healthcare, Global, Central Nervous System, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 59
Data table 54: Pharmaceutical and Healthcare, Global, Infectious Disease, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 61
Data table 55: Pharmaceutical and Healthcare, Global, Immunology, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 63
Data table 56: Pharmaceutical and Healthcare, Global, Cardiovascular, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 65
Data table 57: Pharmaceutical and Healthcare, Global, Metabolic Disorders, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 67
Data table 58: Pharmaceutical and Healthcare, Global, Dermatology, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 69
Data table 59: Pharmaceutical and Healthcare, Global, Gastrointestinal, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 71
Data table 60: Pharmaceutical and Healthcare, Global, Respiratory, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 73
Data table 61: Pharmaceutical and Healthcare, Global, Hematological Disorders, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 75
Data table 62: Pharmaceutical and Healthcare, North America, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 77
Data table 63: Pharmaceutical and Healthcare, Europe, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 79
Data table 64: Pharmaceutical and Healthcare, Asia-Pacific, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 81
Data table 65: Pharmaceutical and Healthcare, Rest of the World, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 83
Data table 66: Pharmaceutical and Healthcare, Top Financial Advisors, Merger and Acquisition, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 84
Data table 67: Pharmaceutical and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 85
Data table 68: Pharmaceutical and Healthcare, Deals’ Key Financials, World Acquisition Deals, Q1 2010-Q1 2011 86

List of Figures

Chart 1: Pharmaceutical and Healthcare, Global, Number of Deals and Deal Values (US$m), Q1 2010 - Q1 2011 9
Chart 2: Pharmaceutical and Healthcare, Global, Number Of Deals (%) and Deal Values (%), Q1 2011 11
Chart 3: Pharmaceutical and Healthcare, Global, Merger and Acquisition, Number of Deals and Deal Values (US$m), Q1 2010 - Q1 2011 14
Chart 4: Pharmaceutical and Healthcare, Global, Merger and Acquisition s, by Therapy Area, Number of Deals and Deal Values (US$m), by Therapy Area, Q1 2010 - Q1 2011 16
Chart 5: Pharmaceutical and Healthcare, Global, Equity Offering Deals, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 17
Chart 6: Pharmaceutical and Healthcare, Global, Equity Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$m),, Q1 2010 - Q1 2011 20
Chart 7: Pharmaceutical and Healthcare, Global, Debt Offering Deals, Number of Deals and Deal Values (US$m), Q1 2010 - Q1 2011 21
Chart 8: Pharmaceutical and Healthcare, Global, Debt Offering Deals, by Therapy Area, Number of Deals and Deal Values (US$ m),, Q1 2010 - Q1 2011 23
Chart 9: Pharmaceutical and Healthcare, Global, Venture Capital, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 24
Chart 10: Pharmaceutical and Healthcare, Global, Venture Capital Deals, by Stage of Financing, Number Of Deals (%) and Deal Values (%), Q1 2011 26
Chart 11: Pharmaceutical and Healthcare, Global, Venture Capital Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2010 - Q1 2011 27
Chart 12: Pharmaceutical and Healthcare, Global, Top Venture Financing Firms, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 28
Chart 13: Pharmaceutical and Healthcare, Global, Private Equity, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 30
Chart 14: Pharmaceutical and Healthcare, Global, Private Equity Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), by Therapy Area, Q1 2010 - Q1 2011 32
Chart 15: Pharmaceutical and Healthcare, Global, Partnerships, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 33
Chart 16: Pharmaceutical and Healthcare, Global, Partnership Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 34
Chart 17: Pharmaceutical and Healthcare, Global, Partnership Deals, Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 35
Chart 18: Pharmaceutical and Healthcare, Global, Partnership Deals, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 38
Chart 19: Pharmaceutical and Healthcare, Global, Partnership Deals, by Phase, Q1 2010 - Q1 2011 39
Chart 20: Pharmaceutical and Healthcare, Global, Partnership Deals, by Phase, by Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 40
Chart 21: Pharmaceutical and Healthcare, Global, Licensing Agreements, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 41
Chart 22: Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, by Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 42
Chart 23: Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 45
Chart 24: Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, by Therapy Area, Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 46
Chart 25: Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, by Phase, Number Of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 47
Chart 26: Pharmaceutical and Healthcare, Global, Licensing Agreement Deals, by Phase, by Upfront and Milestone Payment and Deal Values (US$ m), Q1 2010 - Q1 2011 48
Chart 27: Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value vs Median Deal Value, (US$m), Q1 2010 - Q1 2011 49
Chart 28: Pharmaceutical and Healthcare, World Acquisitions, Average P/E of Acquired Firms, Q1 2010 - Q1 2011 50
Chart 29: Pharmaceutical and Healthcare, World Acquisitions, Average EV/EBITDA of Acquired Firms, Q1 2010 - Q1 2011 51
Chart 30: Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value per Operating Profit, Q1 2010 - Q1 2011 52
Chart 31: Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value Per Share vs Average March ket Price Per Share), Q1 2010 - Q1 2011 53
Chart 32: Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value Per Share vs Average Book Value Per Share, Q1 2010 - Q1 2011 54
Chart 33: Pharmaceutical and Healthcare, World Acquisitions, Average Deal Value Per Sales, Q1 2010 - Q1 2011 55
Chart 34: Pharmaceutical and Healthcare, Global, Oncology, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 56
Chart 35: Pharmaceutical and Healthcare, Global, Central Nervous System, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 58
Chart 36: Pharmaceutical and Healthcare, Global, Infectious Disease, Number of Deals and Deal Value (US$ m), Q1 2010 - Q1 2011 60
Chart 37: Pharmaceutical and Healthcare, Global, Immunology, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 62
Chart 38: Pharmaceutical and Healthcare, Global, Cardiovascular, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 64
Chart 39: Pharmaceutical and Healthcare, Global, Metabolic Disorders, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 66
Chart 40: Pharmaceutical and Healthcare, Global, Dermatology, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 68
Chart 41: Pharmaceutical and Healthcare, Global, Gastrointestinal, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 70
Chart 42: Pharmaceutical and Healthcare, Global, Respiratory, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 72
Chart 43: Pharmaceutical and Healthcare, Global, Hematological Disorders, Merger and Acquisition Deal Summary, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 74
Chart 44: Pharmaceutical and Healthcare, North America, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 76
Chart 45: Pharmaceutical and Healthcare, Europe, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 78
Chart 46: Pharmaceutical and Healthcare, Asia-Pacific, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 80
Chart 47: Pharmaceutical and Healthcare, Rest of the World, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 82
Chart 48: Pharmaceutical and Healthcare, Top Financial Advisors, Merger and Acquisition, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 84
Chart 49: Pharmaceutical and Healthcare, Global, Top Financial Advisors, Equity Offerings, Number of Deals and Deal Values (US$ m), Q1 2010 - Q1 2011 85

Companies Mentioned

View This Report »

Find all the market research you need - instantly, in one place.

+1.2 Million Research Documents & Statistics +200,000 Trusted Public Sources 350 Industries With Global Coverage

24/7 Customer Support

Talk to Amrita

+1 718 303 2019

Purchase Reports From Reputable Market Research Publishers

Vertical-Cavity Surface-Emitting Lasers (VCSEL) : Technologies and Global Markets

Vertical-Cavity Surface-Emitting Lasers (VCSEL) : Technologies and Global Markets

  • $ 6 650
  • Industry report
  • June 2014
  • by BCC Research

The use of vertical-cavity surface-emitting lasers (VCSELs) has increased in the optical communications industry in the past 15 years. This spurring demand can be attributed to the increasing demand of ...

Merger and Acquisition Trends in the Global Food and Beverage Industry

Merger and Acquisition Trends in the Global Food and Beverage Industry

  • $ 6 000
  • Industry report
  • May 2014
  • by Frost & Sullivan

Average Deal Values are on the Rise This study analyzes the merger and acquisition (M&A) transactions that have taken place in the global food and beverage industry between January 2007 and December 2013. ...

Workflow Management System Market by Workflow System Types (Production, Messaging-based, Web-based, Suite-based, Others), Users (SMBs, Enterprises), Deployment Model (Cloud, On-premise) - Market Forecasts and Analysis (2014-2019)

Workflow Management System Market by Workflow System Types (Production, Messaging-based, Web-based, Suite-based, Others), Users (SMBs, Enterprises), Deployment Model (Cloud, On-premise) - Market Forecasts and Analysis (2014-2019)

  • $ 4 650
  • Industry report
  • May 2014
  • by MarketsandMarkets

Workflow management systems comprise information management, document management, automation of work procedures, comprehensive conceptualization, and model building of business operations. Workflow management ...


ReportLinker is an award-winning market research solution that finds, filters and organizes the latest industry data so you get all the market research you need - quickly, in one place.